Preferred Label : brivaracetam;
UMLS semantic type : T109 - Organic Chemical; T121 - Pharmacologic Substance;
Is substance : O;
Origin ID : M0497062;
UMLS CUI : C1699861;
Currated CISMeF NLP mapping
- MeSH narrower concept(s)
- Related record
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
http://www.has-sante.fr/portail/jcms/c_2664617/fr/briviact
http://www.has-sante.fr/portail/jcms/c_2664617/fr/briviact-brivaracetam-antiepileptique
2016
false
false
false
France
French
treatment outcome
brivaracetam
brivaracetam
brivaracetam
drug therapy, combination
anticonvulsants
anticonvulsants
adult
adolescent
epilepsies, partial
administration, oral
infusions, intravenous
injections, intravenous
evaluation of the transparency committee
insurance, health, reimbursement
guidelines for drug use
brivaracetam
brivaracetam
pyrrolidinones
pyrrolidinones
---
https://www.ema.europa.eu/medicines/human/EPAR/briviact-italy-nubriveo
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
brivaracetam
brivaracetam
brivaracetam
europe
drug approval
drug therapy, combination
anticonvulsants
anticonvulsants
adult
adolescent
epilepsies, partial
drug interactions
pregnancy
breast feeding
administration, oral
infusions, intravenous
drug monitoring
product surveillance, postmarketing
contraception
aged
SV2A protein, human
drug evaluation, preclinical
injections, intravenous
brivaracetam
brivaracetam
pyrrolidinones
pyrrolidinones
membrane glycoproteins
nerve tissue proteins
---
